Sk. Ballas et al., Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea, BR J HAEM, 105(2), 1999, pp. 491-496
In this project we have prospectively studied the erythropoietic activity i
n patients with sickle cell anaemia (SS) before and after treatment with hy
droxyurea (HU). Some of the patients were enrolled in a double-blind placeb
o controlled trial of HU in patients with SS and others were enrolled in an
open label study. Determinants of erythropoietic activity included the ret
iculocyte count, red blood cell (RBC) survival by the Cr-51 method, plasma
Fe-59 clearance, plasma iron turnover (PIT), erythron transferrin uptake (E
TU), RBC production/destruction rate, and RBC Fe utilization, Therapy with
HU increased the mean corpuscular volume (MCV), haemoglobin (Hb)F, RBC surv
ival and t(1/2) (59)Pe clearance; it decreased the reticulocyte count, the
white blood cell (WBC) count, ETU, and the PIT. Most of the changes in para
meters of erythropoiesis could be explained by the increase in Cr-51 RBC su
rvival after therapy with HU. Together the data showed that in selected pat
ients the net effect of HU on Hb level was a function of the difference bet
ween the suppressive effect of HU (decreased RBC production) and the increa
se in RBC survival. In the majority of patients who responded to HU, there
was a preferential effect on RBC survival.